Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Contemporary Management of HIV 2021: Emerging Paradigms in ART

Listen as expert faculty consider important clinical questions related to rapid ART initiation, long-acting antiretroviral drugs, and 2-drug regimens for ART, with an emphasis on the role of new and emerging strategies in the treatment of HIV.
Paul E. Sax, MD
Released: August 25, 2021

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:

  • The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period
  • The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosis
  • A rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse events
  • The ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPV
  • SWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effective
  • GEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDF
  • TANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimen

In addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.

Information on this Educational Activity

Faculty

Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul E. Sax, MD, has disclosed that he has served as a consultant or on a scientific advisory board for Gilead Sciences, GlaxoSmithKline/ViiV, Janssen, and Merck and that he has received funds for research support from Gilead Sciences, GlaxoSmithKline/ViiV, and Merck.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Clinical Care Options (CCO) and Dr. Josep Llibre: Perspective on the landscape of ART options for highly treatment-experienced patients with HIV

Josep M. Llibre, MD, PhD Released: October 18, 2021

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021

Audio from Dr. Milena Murray and Clinical Care Options (CCO): Recommended strategies for managing missed CAB plus RPV LA injections are available and are informed by pharmacokinetic modeling

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Released: October 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue